ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 683

HRCT Predictors Of Decline In FVC% predicted—Implications For Cohort Enrichment For Scleroderma Lung Disease (SLD) Trials

Dinesh Khanna1, Chi-hong Tseng2, Robert D. Suh3, Fereidoun Abtin4, Athol U. Wells5, Donald Tashkin6 and Jonathan Goldin7, 1University of Michigan, Ann Arbor, MI, 2Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3UCLA Department of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, CA, 4Radiology, University of California Los Angeles Medical Center, Santa Monica, CA, 5Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, 6Medicine, University of California at Los Angeles, Los Angeles, CA, 7Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Moderate-to-severe HRCT-defined lung involvement (total lung involvement or fibrosis) is a predictor of decline in FVC% predicted and mortality in SLD. Various staging systems have been proposed to evaluate lung involvement in SLD: 1. Visual read of maximum fibrosis score (MaxFib) calculated from the zone with the worst extent of abnormality (maximum score), 2. Goh and Wells scoring system of limited vs. extensive disease (visual read of HRCT for total lung involvement of >20% vs. < 20% and incorporation of FVC% predicted of >70% or < 70%, if indeterminate HRCT read), and 3. computer-aided diagnosis (CAD) of quantitative scoring for percentage with fibrosis (QLF) and total lung involvement (QILD) Our objective was to evaluate the performance of different staging systems in the placebo cohort of SLS-I over 1-year period.

Methods: QLF and QILD were assessed using the CAD and maximum fibrosis score (MaxFib) was calculated from the zone with the worst extent of abnormality (maximum score) based on average of 2 thoracic radiologists. 3 thoracic radiologists read the baseline HRCTs from the SLS-I for total lung involvement (as proposed by Goh and Wells) and read by 5% increments and for indeterminate results (15-25% lung involvement), FVC% was used to classify patients into limited vs. extensive disease. Paired t-test was used to assess for statistical significance for change in FVC% predicted (relative change) over 1-year.

Results: 79 patients were randomized to placebo group; 55 completed the 1-year study. Of these, 48 had FVC% data at baseline and 12 months and good quality HRCT and were included in the analysis. 60% of patients had MaxFib of >25%, 66% were classified as extensive disease, 11% and 79% had >20% QLF and QILD, respectively. Greater cut off for each staging system was associated with greater decline in FVC% predicted at 1-year (Table).

Conclusion: HRCT-defined lung involvement is a predictor of decline in FVC% predicted over 1 year using different staging systems. The choice of system incorporated in a trial depends on the feasibility and available expertise.

N

Decline in FVC% predicted, Mean (SD)

P value

HRCT Fibrosis score

0-25%

26-100%

19

29

1.1 (14.2)

-9.6 (12.5)

.009

Limited disease

Extensive disease

16

32

2 .0(15)

-9.0 (12)

.009

Whole QILD

< 20%

>20%

10

37

-0.03 (8.08)

-6.8 (15.3)

.07

Whole QLF

< 20%

>20%

42

5

-4.2 (13.8)

-15.4 (15.4)

.09


Disclosure:

D. Khanna,

NIH, Scleroderma Fdn,

2,

Actelion, BMS, Merck, DIGNA, Bayer, Gilead, United Therapeutics, Roche,

5;

C. H. Tseng,
None;

R. D. Suh,
None;

F. Abtin,
None;

A. U. Wells,
None;

D. Tashkin,
None;

J. Goldin,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hrct-predictors-of-decline-in-fvc-predicted-implications-for-cohort-enrichment-for-scleroderma-lung-disease-sld-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology